Diagnostik und Therapie interstitieller Lungenerkrankungen

Summary

Interstitial lung diseases (ILD) are a heterogeneous group of parenchymal lung disorders eventually resulting in respiratory failure that can be classified into those with known and unknown causes. ILD are characterized by deposition of cellular and non-cellular components into the lung parenchyma but vary widely in etiology, clinico-radiologic presentation, histiopathologic features, and clinical course. A combination of clinical context, medical and environmental history, physiologic testing, lung imaging, serologic testing and histiologic findings obtained through bronchoscopic or surgical lung biopsy provides the basis for a precise diagnosis. In particular, high-resolution computed tomography of the chest and recognition of the prognostic importance of separating usual interstitial pneumonia (UIP) from other idiopathic interstitial pneumonias (IIP) have profoundly changed the management of patients with ILD. Besides, smoking cessation, avoidance of antigen or inorganic dust exposure, corticosteroids alone or in combination with azathioprine and cyclophosphamide are still the mainstay of therapy for most entities. However, the poor response rates to immunosuppressive therapy for UIP patients and frequent adverse effects highlight the need for new therapeutic strategies confirmed by randomized clinical trials to guide treatment. So far, lung transplantation remains the treatment of last resort for eligible patients with progressive lung fibrosis and timely referral for transplant evaluation is mandatory owing to limited donor availability.

interstitielle Lungenerkrankungen - gewöhnliche interstitielle Pneumonie - idiopathische Lungenfibrose - Lungentransplantation

interstitial lung diseases - usual interstitial pneumonia - idiopathic pulmonary fibrosis - lung transplantation

Literatur

• 1 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.  Am J Respir Crit Care Med. 2002;  165 (2) 277-304
• 2 American Thoracic Society . Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).  Am J Respir Crit Care Med. 2000;  161 (2 Pt 1) 646-64
• 3 Behr J, Ryu J H. Pulmonary hypertension in interstitial lung disease.  Eur Respir J. 2008;  31 (6) 1357-67
• 4 Bradley B, Branley H M, Egan J J. et al . British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.  Thorax. 2008;  63 Suppl 5 v1-58
• 5 Coultras D B, Hubbard R. Epidemiology of idiopathic pulmonary fibrosis. In: Lynch III JP Idiopathic pulmonary fibrosis, lung biology in health and disease. New York; Marcel Dekker 2004: 772
• 6 Demedts M, Behr J, Buhl R. et al, IFIGENIA Study Group . High-dose acetylcysteine in idiopathic pulmonary fibrosis.  N Engl J Med. 2005;  353 (21) 2229-42
• 7 Demedts M, Wells A U, Antó J M. et al . Interstitial lung diseases: an epidemiological overview.  Eur Respir J Suppl. 2001;  32 2s-16s
• 8 Hoyles R K, Ellis R W, Wellsbury J. et al . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.  Arthritis Rheum. 2006;  54 (12) 3962-70
• 9 Iannuzzi M C, Rybicki B A, Teirstein A S. Sarcoidosis.  N Engl J Med. 2007;  357 (21) 2153-65
• 10 Judson M A. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment.  Am J Med Sci. 2008;  335 (1) 26-33
• 11 King Jr T E. Clinical advances in the diagnosis and therapy of the interstitial lung diseases.  Am J Respir Crit Care Med. 2005;  172 (3) 268-79
• 12 Leuchte H H, Baumgartner R A, Nounou M E. et al . Brain natriuretic peptide is a prognostic parameter in chronic lung disease.  Am J Respir Crit Care Med. 2006;  173 (7) 744-50
• 13 Madison J M. Hypersensitivity pneumonitis: clinical perspectives.  Arch Pathol Lab Med. 2008;  132 (2) 195-8
• 14 Magnussen H, Goeckenjan G, Köhler D. et al . Guidelines to long-term oxygen therapy.  Pneumologie. 2001;  55 (10) 454-64
• 15 Meyer K C. Bronchoalveolar lavage as a diagnostic tool.  Semin Respir Crit Care Med. 2007;  28 (5) 546-60
• 16 Olschewski H, Hoeper M M, Borst M M. et al . Diagnosis and therapy of chronic pulmonary hypertension.  Pneumologie. 2006;  60 (12) 749-71
• 17 Orens J B, Estenne M, Arcasoy S. et al . International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2006;  25 (7) 745-557
• 18 Ryu J H, Daniels C E, Hartman T E. et al . Diagnosis of interstitial lung diseases.  Mayo Clin Proc. 2007;  82 (8) 976-86
• 19 Swigris J J, Olson A L, Fischer A. et al . Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.  Chest. 2006;  130 (1) 30-6
• 20 Travis W D, Hunninghake G, King Jr T E. et al . Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.  Am J Respir Crit Care Med. 2008;  177 (12) 1338-47